Goldman Sachs Group, Inc. (The) Upgrades Acorda Therapeutics Inc (ACOR) to “Neutral”
Acorda Therapeutics Inc (NDAQ:ACOR) was upgraded by equities research analysts at Goldman Sachs Group, Inc. (The) from a “sell” rating to a “neutral” rating in a research note issued to investors on Wednesday.
Acorda Therapeutics (NDAQ:ACOR) opened at 25.30 on Wednesday. Acorda Therapeutics has a one year low of $16.40 and a one year high of $37.36. The firm’s 50-day moving average price is $21.40 and its 200 day moving average price is $21.73. The company’s market capitalization is $1.15 billion.
This news story was originally reported by Daily Political and is the sole property of of Daily Political. If you are viewing this news story on another domain, it was stolen and reposted in violation of United States and international copyright and trademark laws. The original version of this news story can be viewed at http://www.dailypolitical.com/2017/02/16/goldman-sachs-group-inc-the-upgrades-acorda-therapeutics-inc-acor-to-neutral.html.
About Acorda Therapeutics
Acorda Therapeutics, Inc is a biopharmaceutical company. The Company is engaged in the identification, development and commercialization of therapies that restore function and recovers the lives of people with neurological disorders. Its commercial products include Ampyra, Fampyra, Zanaflex Capsules and a generic version of the capsules, Zanaflex tablets and Qutenza.
Receive News & Ratings for Acorda Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acorda Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.